abs378.txt	introduction		time-to-treatment-failure	(ttf)	is	the	interval	from	chemotherapyinitiation	to	premature	discontinuation		we	evaluated	ttf	based	on	age	methods		pooled	analyses	were	conducted	with	first-line	chemotherapy	trials	foradvanced	nsclc	(calgb	9730		30203		and	30801)		comparisons	among	patients	whowere	65	years	and	older	and	70	years	and	older	were	performed	for	ttf	(primaryendpoint)		reasons	for	early	chemotherapy	cessation		grade	3+	adverse	events		andoverall	survival	results		among	1006	patients		460	(46%)	were	older	than	65	years	of	age		onehundred	forty-five	older	patients	(32%	of	this	age	cohort)	completed	all	sixplanned	chemotherapy	cycles	as	did	170	(32%)	younger	patients		median	ttf	was	2	9months	(95%	confidence	interval		2	7-	3	2)	in	older	patients	and	3	months	(95%confidence	interval		2	9-3	5)	in	younger	patients		adjustment	for	performancestatus	and	stratification	by	chemotherapy	by	trial	yielded	no	statisticallysignificant	age-based	difference	in	ttf		however		reasons	for	early	chemotherapycessation	differed	between	age	groups	(multivariate	p	=	0	004)		older	patientswere	less	likely	to	discontinue	from	cancer	progression	(41%	versus	55%)	and	morelikely	from	toxicity	or	patient	choice	(16%	and	15%		respectively)	compared	toyounger	patients	(13%	and	6%		respectively)		older	patients	were	more	likely	toexperience	grade	3+	adverse	events	(86%	versus	79%)	with	no	statisticallysignificant	difference	in	survival		an	age	cutpoint	of	70+	years	showed	nodifference	in	ttf		a	lower	trend	of	early	cessation	due	to	cancer	progression	and	somewhat	shorter	older	patient	survival	conclusions		ttf	was	comparable	between	older	and	younger	patients		butdifferent		age-based		and	potentially	modifiable	reasons	account	for	it	
